NIH recognizes Hygieia as a STTR grant success story
In 2010, the National Institutes of Health recognized the potential of Hygieia’s unique insulin management technology and invested in it. As part of the institute’s commitment to “Turning discovery into health®”, Hygieia was the recipient of a Phase I grant from the institute’s Small Business Technology Transfer program.
Every year, that program awards grants to small businesses in states across the country. In this way, the NIH is an important source of capital that enables early stage companies to create innovative health technologies.
“The Phase I grant helped us develop the technology behind the d-Nav program and provided a vote of confidence that helped us gain private investors,” said Eran Bashan, Ph.D., co-founder of Hygieia. “That led to a much bigger Phase II grant in 2013, which helped fund a randomized controlled clinical study proving that our technology worked.”
Today, 90 percent of the patients with Type 2 diabetes taking advantage of Hygieia’s d-Nav® Insulin Management Program significantly improve their A1c within three months.
What’s more, Hygieia holds 13 US patents, has provided some 3,000 patient years of care, and prescribed more than 4 million insulin doses. For those facts and more, the NIH has recognized Hygieia and its ground-breaking d-Nav app as a success story.
“The NIH had the vision in 2010 to help Hygieia bring the future to life. This was well before anyone was talking about digital health,” said Bashan.
In June, Hygieia began offering a fully virtual option of its d-Nav program for both new and existing patients. That’s just one way the company is expanding access to its revolutionary d-Nav insulin management program. Hygieia is accepted by most insurance plans including Medicare.